TY - JOUR T1 - Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 2637 LP - 2644 DO - 10.21873/anticanres.14234 VL - 40 IS - 5 AU - RYOTA TANAKA AU - KEN KAGEYAMA AU - KENJIRO KIMURA AU - SHINPEI EGUCHI AU - JUN TAUCHI AU - HIROJI SHINKAWA AU - GO OHIRA AU - SADAAKI YAMAZOE AU - AKIRA YAMAMOTO AU - SHOGO TANAKA AU - RYOSUKE AMANO AU - HIROAKI TANAKA AU - MASAKAZU YASHIRO AU - SHOJI KUBO AU - MASAICHI OHIRA Y1 - 2020/05/01 UR - http://ar.iiarjournals.org/content/40/5/2637.abstract N2 - Background/Aim: There is rapid progression and widespread use of patient-derived tumor xenografts (PDX) in translational pancreatic cancer research. This study aimed to establish a liver transplant PDX model using cryopreserved primary pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: Primary PDAC from 10 patients were cryopreserved and transplanted into immunodeficient mice using the liver pocket method. H&E staining and immunohistochemical staining, such as Ki-67, p53, Smad4, and MUC1 were used to evaluate engraftment and histological similarities. Results: Patient-derived xenograft placement was successful in six cases (60%), and 10 mice (33.3%). The Ki-67 index of primary PDAC and the cryopreservation duration were significantly related to successful engraftment (p=0.003 and p=0.007, respectively). Conclusion: In this study, we succeeded in establishing a liver transplant PDX mouse model as a preclinical platform. The successful engraftment was affected by the cryopreservation duration and could be detected by the Ki-67 index. ER -